Ginkgo Bioworks Holdings, Inc. (DNA) stock
DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/3013% below fair value
$8.44+0.12 (+1.44%)
Close on Nov 18, 2026Market cap $568.35MP/E –Yield –
Ginkgo Bioworks revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Ginkgo Bioworks's revenue for the twelve months ending Jun 30, 2026 was $111.86M, down 46.8% year over year. For fiscal 2025 it was $170.16M, down 25.1% from the year before. The highest annual figure on record is $477.71M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $170.16M | -25.1% |
| FY2024 | Dec 31, 2024 | $227.04M | -9.7% |
| FY2023 | Dec 31, 2023 | $251.46M | -47.4% |
| FY2022 | Dec 31, 2022 | $477.71M | +52.2% |
| FY2021 | Dec 31, 2021 | $313.84M | +309.4% |
| FY2020 | Dec 31, 2020 | $76.66M | +41.5% |
| FY2019 | Dec 31, 2019 | $54.18M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $20.16M | -48.5% |
| Q1 FY2026 | Mar 31, 2026 | $19.47M | -49.1% |
| Q4 FY2025 | Dec 31, 2025 | $33.40M | -23.8% |
| Q3 FY2025 | Sep 30, 2025 | $38.84M | -56.4% |
| Q2 FY2025 | Jun 30, 2025 | $39.13M | -30.4% |
| Q1 FY2025 | Mar 31, 2025 | $38.23M | +0.8% |
| Q4 FY2024 | Dec 31, 2024 | $43.85M | +26.2% |
| Q3 FY2024 | Sep 30, 2024 | $89.05M | +60.6% |
| Q2 FY2024 | Jun 30, 2024 | $56.21M | -30.2% |
| Q1 FY2024 | Mar 31, 2024 | $37.94M | -53.0% |
| Q4 FY2023 | Dec 31, 2023 | $34.76M | -64.6% |
| Q3 FY2023 | Sep 30, 2023 | $55.43M | -16.5% |
| Q2 FY2023 | Jun 30, 2023 | $80.57M | -44.3% |
| Q1 FY2023 | Mar 31, 2023 | $80.70M | -52.1% |
| Q4 FY2022 | Dec 31, 2022 | $98.29M | -33.8% |
| Q3 FY2022 | Sep 30, 2022 | $66.40M | -14.4% |
| Q2 FY2022 | Jun 30, 2022 | $144.62M | +231.4% |
| Q1 FY2022 | Mar 31, 2022 | $168.41M | +281.9% |
| Q4 FY2021 | Dec 31, 2021 | $148.49M | +363.2% |
| Q3 FY2021 | Sep 30, 2021 | $77.61M | +483.4% |
| Q2 FY2021 | Jun 30, 2021 | $43.64M | – |
| Q1 FY2021 | Mar 31, 2021 | $44.10M | – |
| Q4 FY2020 | Dec 31, 2020 | $32.06M | – |
| Q3 FY2020 | Sep 30, 2020 | $13.30M | – |
See a number that looks wrong?